Rapidly generate validated multi-gene knockout strains in S. cerevisiae using a multiplex CRISPR/Cas9 system.
Our service combines CRISPR/Cas9‑mediated genome editing with marker recycling to enable efficient, iterative disruption of multiple genes in Saccharomyces cerevisiae. Ideal for functional genomics, metabolic engineering, and synthetic biology applications.
A stepwise process combining custom gRNA design, plasmid‑based Cas9 delivery, and iterative marker recycling to achieve clean multi‑gene deletions.
We design multiple guide RNAs targeting your genes of interest using proprietary algorithms that minimize off‑target potential. Each gRNA is cloned into a CRISPR/Cas9 expression plasmid along with a selection marker (auxotrophic or drug resistance).
Yeast strains are transformed with the CRISPR plasmid(s) and selected on appropriate media. For sequential knockouts, the marker is recycled using counter‑selection or Cre‑lox recombination, allowing reuse of the same marker for the next round.
Number of targets, marker selection, and editing strategy are scoped per project. We accommodate both single‑round multiplex and iterative approaches.
Each deletion is confirmed by colony PCR and Sanger sequencing. The final strain is purified to monoclonal status and archived.
Receive validated strain(s), plasmid constructs, and a detailed QC report — all structured to integrate into your research or production pipeline.
Each project delivers a fully documented, monoclonal knockout strain suitable for immediate use.
All parameters are defined during project design; the table below outlines typical ranges.
| Parameter | Typical project scope |
|---|---|
| Number of target genes | As scoped; typically 2–6 per project, scalable via iterative rounds |
| Editing strategy | Gene disruption via indel or complete open reading frame deletion |
| Selection markers available | Auxotrophic (URA3, LEU2, HIS3, TRP1) or drug resistance (G418, nourseothricin) |
| Marker recycling | Included for sequential knockouts (Cre‑lox or 5‑FOA counter‑selection) |
| Verification method | Colony PCR + Sanger sequencing for each edited locus |
| Off‑target analysis | In silico prediction; targeted amplicon sequencing when scoped |
| Strain purification | Single‑colony isolation to support monoclonal genotype |
| Technical support | Named scientific contact at project start; milestone review calls; email response within 1 business day |
A streamlined, five‑stage workflow that keeps you informed at every step.
You provide the list of target genes (or we help identify candidates). We design gene‑specific guide RNAs using algorithms that balance on‑target efficiency and minimize potential off‑target activity, then confirm each gRNA target sequence in your strain background.
Each gRNA is cloned into a CRISPR/Cas9 expression plasmid carrying a selection marker. The plasmid(s) are transformed into Saccharomyces cerevisiae using an optimized protocol (lithium acetate or electroporation) and plated on selective media.
Transformant colonies are screened by colony PCR to identify candidates with the desired edit. Positive clones are streaked for purification and subjected to additional PCR verification across each target locus.
When multiple rounds of editing are needed, the selection marker is excised (e.g., Cre‑lox or 5‑FOA counter‑selection). The marker‑free strain is then used for the next round of transformation with new gRNA plasmids.
The final monoclonal strain is confirmed by PCR and Sanger sequencing for all edited loci. A comprehensive QC report including gel images, chromatograms, and off‑target summary is prepared. The validated strain and associated plasmids are shipped.
Our service supports a broad range of basic and applied yeast research.
Systematically disrupt multiple genes to study synthetic lethality, genetic interaction networks, and pathway redundancy in Saccharomyces cerevisiae.
Eliminate competing pathways or regulatory repressors to redirect carbon flux toward desired products such as ethanol, lactate, or advanced biofuels.
Create minimal genome strains by knocking out non‑essential genes, providing a cleaner host for synthetic circuits or heterologous pathway integration.
Practical answers about our multi‑gene knockout service.
The number of targets is scoped per project and depends on factors such as gene essentiality, editing strategy, and desired timeline. Typical projects involve 2–6 genes, with iterative rounds enabling larger sets. We will discuss feasibility during the initial consultation.
Every edited locus is confirmed by colony PCR and Sanger sequencing.The final strain is purified to monoclonal origin and re‑screened to support genotype stability.
Yes. We routinely handle S. cerevisiae laboratory strains (e.g., BY4741, W303, CEN.PK, S288C derivatives). For other backgrounds, a preliminary transformation efficiency test may be performed. Please provide strain details during project scoping.
Project duration depends on the number of target genes and the chosen editing strategy. A project involving 2–3 genes with one round of marker recycling generally completes a timeline confirmed during project scoping. Exact timelines are provided in the project proposal.
Get a customized quote for your Saccharomyces cerevisiae Multi-Gene Knockout Strain Construction Service project. Our experts will respond within 24 hours.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.